Literature DB >> 35648190

Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Slobodan P Rendić1, Rachel D Crouch2, F Peter Guengerich3.   

Abstract

This is an overview of the metabolic reactions of drugs, natural products, physiological compounds, and other (general) chemicals catalyzed by flavin monooxygenase (FMO), monoamine oxidase (MAO), NAD(P)H quinone oxidoreductase (NQO), and molybdenum hydroxylase enzymes (aldehyde oxidase (AOX) and xanthine oxidoreductase (XOR)), including roles as substrates, inducers, and inhibitors of the enzymes. The metabolism and bioactivation of selected examples of each group (i.e., drugs, "general chemicals," natural products, and physiological compounds) are discussed. We identified a higher fraction of bioactivation reactions for FMO enzymes compared to other enzymes, predominately involving drugs and general chemicals. With MAO enzymes, physiological compounds predominate as substrates, and some products lead to unwanted side effects or illness. AOX and XOR enzymes are molybdenum hydroxylases that catalyze the oxidation of various heteroaromatic rings and aldehydes and the reduction of a number of different functional groups. While neither of these two enzymes contributes substantially to the metabolism of currently marketed drugs, AOX has become a frequently encountered route of metabolism among drug discovery programs in the past 10-15 years. XOR has even less of a role in the metabolism of clinical drugs and preclinical drug candidates than AOX, likely due to narrower substrate specificity.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bioactivation; Flavin-containing monooxygenase; Molybdenum hydroxylases; Monoamine oxidase; NAD(P)H quinone oxidoreductase; Natural products; Xenobiotics

Mesh:

Substances:

Year:  2022        PMID: 35648190      PMCID: PMC9159052          DOI: 10.1007/s00204-022-03304-3

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   6.168


  713 in total

Review 1.  The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines.

Authors:  Sharon K Krueger; Jonathan E Vandyke; David E Williams; Ronald N Hines
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

2.  The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O).

Authors:  F Stirpe; E Della Corte
Journal:  J Biol Chem       Date:  1969-07-25       Impact factor: 5.157

Review 3.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

4.  Metabolism of chlorpromazine and promazine in vitro: isolation and characterization of N-oxidation products.

Authors:  A H Beckett; G E Navas; A J Hutt
Journal:  Xenobiotica       Date:  1988-01       Impact factor: 1.908

5.  Methylpiperate derivatives from Piper longum and their inhibition of monoamine oxidase.

Authors:  Seon A Lee; Ji Sang Hwang; Xiang Hua Han; Chul Lee; Min Hee Lee; Sang Gil Choe; Seong Su Hong; Dongho Lee; Myung Koo Lee; Bang Yeon Hwang
Journal:  Arch Pharm Res       Date:  2008-06-19       Impact factor: 4.946

6.  Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans.

Authors:  Pan Deng; Dafang Zhong; Kate Yu; Yifan Zhang; Ting Wang; Xiaoyan Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3.

Authors:  D H Lang; C K Yeung; R M Peter; C Ibarra; R Gasser; K Itagaki; R M Philpot; A E Rettie
Journal:  Biochem Pharmacol       Date:  1998-10-15       Impact factor: 5.858

8.  Species variation in hepatic aldehyde oxidase activity.

Authors:  C Beedham; S E Bruce; D J Critchley; Y al-Tayib; D J Rance
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Oct-Dec       Impact factor: 2.441

9.  Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.

Authors:  Seung Cheol Baek; Myung-Gyun Kang; Ji-Eun Park; Jae Pil Lee; Hanna Lee; Hyung Won Ryu; Chul Min Park; Daeui Park; Myoung-Lae Cho; Sei-Ryang Oh; Hoon Kim
Journal:  Bioorg Med Chem Lett       Date:  2019-01-18       Impact factor: 2.823

10.  Monoamine oxidase inhibitory activities of indolylalkaloid toxins from the venom of the colonial spider Parawixia bistriata: functional characterization of PwTX-I.

Authors:  Daniel M Saidemberg; Marco A B Ferreira; Tatiane N Takahashi; Paulo C Gomes; Lilian M M Cesar-Tognoli; Luiz C da Silva-Filho; Cláudio F Tormena; Gil V J da Silva; Mario S Palma
Journal:  Toxicon       Date:  2009-06-06       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.